News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Lonza CEO Quits As Profit Tumbles, Shares Drop
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Lonza (LONN.VX: Quote, Profile, Research) Chief Executive Markus Gemuend quit on Tuesday as the specialty chemicals maker posted a dire 59 percent drop in 2003 profit, hit by oversupply in the biotechnology market.
Twitter
LinkedIn
Facebook
Email
Print
People
Lonza
MORE ON THIS TOPIC
Regulatory
Acting CBER, CDER heads become permanent as FDA works to restore stability
September 9, 2026
·
2 min read
·
Tristan Manalac
IPO
2026 IPO stock tracker: How newly public biotechs are performing
September 9, 2026
·
1 min read
·
Gabrielle Masson
Venture capital
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
September 9, 2026
·
2 min read
·
Annalee Armstrong
Funding
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
September 9, 2026
·
2 min read
·
Tristan Manalac
